

MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β -thalassaemia

Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020